MiNK Therapeutics Presents Promising Clinical Activity of AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Gastric Cancer Patients
New York, May 22, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a leading clinical-stage biopharmaceutical company specializing in allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, revealed new clinical data regarding agenT-797 at the American Thoracic Society (ATS) Annual Meeting. The findings presented shed light on the drug’s efficacy in a complex case of severe ARDS, augmenting the growing body of evidence demonstrating its clinical activity in patients with severe ARDS.
MiNK Therapeutics’ mission is to pioneer the discovery, development, and commercialization of allogeneic iNKT cell therapies. These therapies have the potential to revolutionize the treatment landscape for cancer and other immune-mediated diseases. AgenT-797, one of the company’s key investigational products, has shown significant promise in the treatment of immune-compromised patients suffering from severe ARDS and gastric cancer.
In a recent clinical trial, MiNK Therapeutics administered agenT-797 to a patient with severe ARDS, achieving remarkable clinical activity. The translational and mechanistic insights gained from this case contribute to the ever-expanding dataset on the drug’s potential in treating severe ARDS. Furthermore, agenT-797 has demonstrated the ability to overcome resistance to immune checkpoint inhibitors, as evidenced by findings published in Oncogene, where it displayed durable disease stabilization and a confirmed response in patients with chemotherapy and anti-PD-1 refractory gastric cancer.
The company’s commitment to advancing the field of cell therapy is further exemplified by the initiation of a Phase 2 investigator-sponsored study led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center. This study aims to evaluate the efficacy of agenT-797 in second-line gastroesophageal cancer, building upon the positive outcomes observed in MiNKs’ previously published clinical trials.
In a ground-breaking publication in Nature Communications, MiNK Therapeutics demonstrated the improved survival rates associated with the use of agenT-797 in severe respiratory distress. This study solidifies the potential of agenT-797 as a viable treatment option for patients suffering from this life-threatening condition.
The findings presented at the ATS Annual Meeting, along with previous clinical trial data, highlight the efficacy of agenT-797 in both severe ARDS and refractory gastric cancer. These results further affirm MiNK Therapeutics’ commitment to harnessing the potential of allogeneic iNKT cell therapy to address unmet medical needs.
Comments